Welcome to our dedicated page for Cardlytics SEC filings (Ticker: CDLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Cardlytics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Cardlytics's regulatory disclosures and financial reporting.
Cardlytics, Inc. (symbol: CDLX) is the issuer of record for a Form 4/A filing submitted to the SEC.
Cardlytics, Inc. (symbol: CDLX) is the issuer of record for a Form 4/A filing submitted to the SEC.
Cardlytics, Inc. (symbol: CDLX) is the issuer of record for a Form 4/A filing submitted to the SEC.
Cardlytics, Inc. (symbol: CDLX) is the issuer of record for a Form 4/A filing submitted to the SEC.
Cardlytics, Inc. (symbol: CDLX) is the issuer of record for a Form 4/A filing submitted to the SEC.
Cardlytics, Inc. (symbol: CDLX) is the issuer of record for a Form 4/A filing submitted to the SEC.
Cardlytics, Inc. (CDLX) reported insider equity activity by Chief Executive Officer Amit Gupta. On August 16, 2026, Gupta acquired 25,000 shares of common stock upon the vesting and conversion of 25,000 Restricted Stock Units (RSUs), each RSU representing a contingent right to receive one share of common stock. These RSUs relate to two separate 50,000-share RSU awards granted on August 21, 2024 and January 29, 2025, which vest in four equal 25% installments over 24 months following August 16, 2024, subject to continued employment. On August 17–18, 2026, Gupta sold an aggregate of 13,461 shares of common stock in open-market or private transactions at weighted average prices of $3.966 and $4.031 per share, respectively. The filing’s Rule 10b5-1 checkbox indicates these sales were not made pursuant to a Rule 10b5-1 trading plan.
Cardlytics, Inc. (CDLX) is the issuer for a planned sale of common stock under Rule 144 by Amit Gupta. The notice covers up to 6,676 shares of common stock held at Fidelity Brokerage Services LLC, with a Rule 144 calculation reference price of $26,908.29 and an expiration date of August 18, 2026.
The shares to be sold arise from restricted stock vesting on August 14, 2026, characterized as a compensation-related transaction by the issuer. The filer notes that the sale includes an amount necessary to cover a tax obligation from the settlement of a vested equity award distribution.
The filing also lists sales of Cardlytics common stock by Amit Gupta during the prior three months: 6,498 shares on July 2, 2026 for $28,560.72, 9,640 shares on July 6, 2026 for $42,361.14, and 6,785 shares on August 17, 2026 for $26,908.63.
Amit Gupta filed a Form 144 indicating an intent to sell up to 6,785 shares of Cardlytics, Inc. (CDLX) common stock through Fidelity Brokerage Services LLC on or after 08/17/2026 on NASDAQ. The shares relate to restricted stock vesting on 08/14/2026 received as compensation. The filing also lists prior CDLX common stock sales in the last three months.
Cardlytics, Inc. reported Q2 2026 revenue of $36.9 million, down from $58.0 million a year earlier, as a U.S. financial-institution partner exited its platform and Monthly Qualified Users decreased. Continuing-operations net loss was $8.7 million and total net loss was $14.9 million.
The company completed the Bridg business sale, recording a $13.9 million gain in discontinued operations and later selling the 1.81 million PAR shares for $23.0 million, incurring a $2.4 million loss on investments. Cash and cash equivalents declined to $28.0 million, with $15.0 million drawn on a revolving credit facility and $172.5 million of 4.25% Convertible Senior Notes outstanding. Adjusted EBITDA was positive at $1.7 million in Q2, while stockholders’ equity stood at a $16.0 million deficit after a 1‑for‑10 reverse stock split reduced common shares outstanding to about 5.9 million.